Details for Patent: 8,470,359
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,470,359 protect, and when does it expire?
Patent 8,470,359 protects ELIGARD KIT and FENSOLVI KIT and is included in four NDAs.
This patent has sixty-eight patent family members in twenty-six countries.
Summary for Patent: 8,470,359
Title: | Sustained release polymer |
Abstract: | A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months. |
Inventor(s): | Dunn; Richard L. (Fort Collins, CO) |
Assignee: | QLT USA, Inc. (Willmington, DE) |
Application Number: | 11/469,392 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,470,359 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,470,359
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tolmar Therap | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021379-001 | Jul 24, 2002 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING CANCER | See Plans and Pricing | ||
Tolmar Therap | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021488-001 | Feb 13, 2003 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING CANCER | See Plans and Pricing | ||
Tolmar Therap | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021731-001 | Dec 14, 2004 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING CANCER | See Plans and Pricing | ||
Tolmar | FENSOLVI KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 213150-001 | May 1, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,470,359
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 259217 | See Plans and Pricing | |||
Austria | 296088 | See Plans and Pricing | |||
Austria | 458469 | See Plans and Pricing | |||
Australia | 1331200 | See Plans and Pricing | |||
Australia | 2001292931 | See Plans and Pricing | |||
Australia | 2006241376 | See Plans and Pricing | |||
Australia | 2010201645 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |